Boehringer Ingelheim Venture Fund

What Boehringer Ingelheim Venture Fund does

Boehringer Ingelheim Venture Fund (BIVF) is a €350 million evergreen corporate venture capital fund established in 2010 as a wholly-owned subsidiary of Boehringer Ingelheim, headquartered in Ingelheim am Rhein, Germany, with regional offices in Cambridge, Massachusetts (USA) and Hong Kong (China). BIVF operates as a dedicated Seed/Series A investor with company formation expertise, primarily deploying minority equity with voting board seats into pre-clinical biotech companies developing first-in-class, disease-modifying therapeutics. Since inception the fund has invested in over 70 companies (including 7 fund-in-fund vehicles) and currently maintains more than 40 active portfolio companies across six focus areas: oncology (immuno-oncology and targeted therapy), regenerative medicine including cell reprogramming and neurodegeneration, auto-immunity, digital health supporting the pharma value chain, and anti-infectives with an emphasis on antimicrobial resistance.

The underlying technology BIVF finances spans small molecules, biologics, cell therapies, gene therapies, and RNA-based therapeutics, with modalities including engineered T-cell receptors, circular RNA, FOXO3 activators, megakaryocyte-derived extracellular vesicles, bacterial immunotherapy platforms, AI-driven antibacterial discovery, and engineered lysins/bacteriocins. Representative portfolio companies include AgomAb Therapeutics (HGF-driven fibrosis), T-knife Therapeutics (TCR-T cell therapy), RiboX Therapeutics (circular RNA), STRM.BIO (non-viral gene delivery), ArrePath (ML-powered antibacterials), and Aurobac Therapeutics (AMR). BIVF's portfolio also includes AI/digital-native assets such as Aignostics, Brainomix, and Bodyport.

BIVF's business model is structured as a corporate venture capital fund: it does not generate product revenue, and returns accrue to Boehringer Ingelheim through capital appreciation and exits. The fund has facilitated 14 exits since 2010, including six acquisitions by Boehringer Ingelheim (Amal Therapeutics, ICD Therapeutics, ViraTherapeutics, NBE Therapeutics, Abexxa Biologics, T3 Pharmaceuticals) and six to other pharmaceutical or healthcare acquirers (GSK, MSD, Qiagen, JCR Pharma). Investments are sourced through direct outreach, industry networks, and partnerships, with deal sizes ranging from seed rounds (e.g., CHF 10M for TECregen) to Series C support (e.g., $75M+ for Beacon Therapeutics).

Name

Boehringer Ingelheim Venture Fund

Legal name

Boehringer Ingelheim Venture Fund GmbH

Website

http://www.boehringer-ingelheim-venture.com

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

11–50 employees

Short description

Boehringer Ingelheim Venture Fund is a €350M evergreen corporate venture arm of Boehringer Ingelheim that invests Seed/Series A tickets in pre-clinical biotech companies developing first-in-class, disease-modifying therapeutics across oncology, regenerative medicine, auto-immunity, digital health, and anti-infectives.

Ownership category

akta.pro rank

Product category

Venture Capital / Life Sciences Investment

NAICS

Finance and Insurance (52), Other Investment Pools and Funds (5259)

SIC

Investment Advice (6282)

akta.pro primary industry

Venture Capital Fund-of-Funds / Multi-Manager Platforms (FSANAAAJ)

Keywords

• Venture capital funding
• Biotech investments
• Life sciences investing
• Pharmaceutical R&D
• Corporate venture capital

Headquarters

HQ city

Ingelheim Am Rhein

HQ country

Germany

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales

Revenue model

1. Investment Returns: Generates returns through capital appreciation and exits of portfolio companies. The fund has facilitated multiple exits including 6 exits to Boehringer Ingelheim corporation.

Go-to-market motion1 record

Marketing channels5 records

Core offering

Boehringer Ingelheim Venture Fund is a €350M evergreen venture capital fund that provides Seed/Series A financing to early-stage biotech companies developing first-in-class, disease-modifying therapeutics. The fund takes minority shareholder positions with voting board seats, supporting portfolio companies through drug discovery expertise, regulatory guidance, and strategic alignment with Boehringer Ingelheim's pharmaceutical interests. Investment focus spans six therapeutic areas: cancer (immuno-oncology and targeted therapy), regenerative medicine, auto-immunity, digital health, and anti-infectives (AMR).

Product overview

Boehringer Ingelheim Venture Fund is a €350M evergreen venture capital fund established in 2010 with global presence in the EU, US, and China. The fund operates as a dedicated Seed/Series A investor with company formation expertise, primarily investing in pre-clinical assets and platforms. The fund's investment strategy focuses on first-in-class, disease-modifying therapeutics across six main sectors: Cancer (immuno-oncology & targeted therapy), Regenerative Medicine (incl. cell reprogramming & neuro degeneration), Auto-immunity indications, Digital solutions (supporting the pharma value chain), and Infectious disease (focus on AMR). Since inception, the fund has invested in over 70 companies with more than 40 active portfolio companies, having facilitated 14 exits including 6 exits to Boehringer Ingelheim.

Differentiator

Problem solved

Functional benefit

Products and services

• Boehringer Ingelheim Venture Fund A €350M evergreen venture capital fund established in 2010 that invests in pioneering, first-in-class disease-modifying therapeutics across various modalities. The fund focuses on pre-clinical assets and platforms, primarily as a Seed/Series A investor with company formation expertise, seeking minority shareholder positions with voting board seats.
• Oncology (Immuno-Oncology & Targeted Therapy) Portfolio Investment focus on cancer immunotherapy and targeted therapies with portfolio companies including Abalos, Actym Therapeutics, Asgard Therapeutics, QUANTRO Therapeutics, Rgenta, Synthetica Pioneering, Tacalyx, and T-knife.
• Regenerative Medicine Portfolio Investment focus on regenerative medicine including cell reprogramming and neurodegeneration with portfolio companies including AgomAb Therapeutics, DiogenX, HepaRegenix, Libra Therapeutics, Nuevocor, ProTgen, Refoxy Pharmaceuticals, Rewind Therapeutics, RinRi Therapeutics, TECregen, and Thymogenesis.
• Anti-Infectives (AMR) Portfolio Investment focus on antimicrobial resistance with portfolio companies including Aurobac, ArrePath, Centauri Therapeutics, Glox Therapeutics, Obulytix, and smartbax developing novel antibiotics and anti-infective technologies.
• Digital Health Portfolio Investment focus on digital solutions supporting pharma value chain with portfolio companies including Aignostics (AI pathology), Bodyport, Brainomix (AI imaging), C-mo Medical Solutions, Optina Diagnostics, Wellth, and xCures.
• Fund-in-Fund Investments Strategic fund-in-fund investments as part of the portfolio diversification strategy, with 7 fund-in-fund investments included in the over 70 total investments.

Quantifiable outcome

• 14 exits including 6 to Boehringer Ingelheim
• +2 more outcomes

Named customers16 records

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Novartis Venture Fund: Corporate venture capital arm of Novartis, investing in early-stage biotech and digital health with focus on therapeutics platforms. Direct comparable as a major-pharma CVC with similar Seed/Series A strategy and therapeutic breadth.
• Roche Venture Fund: CVC arm of Roche investing in early-stage biotech and diagnostics. Highly comparable — Swiss-headquartered pharma CVC with similar evergreen-style structure and strategic alignment to a large parent.
• Pfizer Ventures: Corporate venture capital arm of Pfizer investing in early-stage biotech across therapeutic areas. Direct CVC peer with comparable thesis on breakthrough therapeutics and similar minority-stake, board-seat approach.
• Sanofi Ventures: Corporate venture capital arm of Sanofi, investing in early-stage biotech and digital health. Direct comparable — major-pharma CVC with similar pre-clinical / early-stage focus and strategic alignment to a top-20 pharmaceutical parent.
• SR One (GSK): Venture capital arm of GSK, investing in early-stage biotech and therapeutics platforms. Direct CVC peer with comparable evergreen-style deployment and minority-stake approach.
• MRL Ventures Fund (Merck): Corporate venture capital arm of Merck (MSD), focused on early-stage therapeutics investments. Direct CVC peer with similar strategic-alignment model and US/EU geographic spread.
• AbbVie Ventures: Corporate venture capital arm of AbbVie investing in early-stage biotech across therapeutic areas. Direct comparable CVC with strategic alignment to a large pharma parent and similar therapeutic breadth.
• JJDC (Johnson & Johnson): CVC arm of Johnson & Johnson, investing across therapeutics, medtech, and digital health. Direct comparable — major-pharma CVC with diversified portfolio and strategic alignment to a top-tier parent.
• AstraZeneca (AInnovation / Alexion Ventures): Corporate venture capital arm of AstraZeneca, investing in early-stage biotech across oncology, rare disease, and digital health. Direct CVC peer with comparable strategic alignment model.
• Lilly Asia Ventures: Venture capital arm of Eli Lilly focused on Asian biotech markets. Direct comparable — pharma CVC with regional-investment mandate that overlaps with BIVF's Asia strategy through its Hong Kong office.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xtwitter.com/BoehringerIng
• YouTubeyoutube.com/user/boehringeringelheim
• Facebookfacebook.com/BoehringerIngelheim
• LinkedInlinkedin.com/company/boehringer-ingelheim
• Instagraminstagram.com/boehringeringelheim

Revenue estimate

Valuation estimate

Number of profiles

Profiles16 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments100 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Boehringer Ingelheim Venture Fund